In 2015, 177Lu-PSMA-617 was first introduced as a promising treatment option for castration-resistant prostate cancer, and 7 years later the results of the phase III VISION trial led to 177Lu-PSMA-617 gaining FDA approval for the treatment of progressive castration-resistant prostate cancer. Here, FOLH1 is linked to prostate carcinoma.